Testing two antibody drugs for HER2-low breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests two antibody-drug conjugates (Enhertu and Datroway) for breast cancer that is HER2-low or HER2-0. It aims to find the best treatment sequence for people whose cancer has stopped responding to prior therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your breast cancer must be HER2-low or HER2-0 (not HER2-positive).
- Your cancer must have spread to other parts of the body (metastatic) or cannot be removed by surgery.
- You must be able to have a tumor biopsy (a needle sample) before and during the study.
- You must have had no more than 1 or 2 prior chemotherapy treatments for metastatic cancer, depending on the study group.
- You cannot have had a topoisomerase I inhibitor before (a type of chemotherapy), unless you are enrolling in a specific group that allows it.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a targeted antibody-drug medicine (trastuzumab deruxtecan, T-DXd) in people with metastatic breast cancer that is HER2-low or HER2 IHC 0. It may help by treating tumors that haven’t previously received anti-HER2 treatment in the metastatic setting.
This study is testing a new drug called trastuzumab deruxtecan (also known as T-DXd) in women with advanced breast cancer that is hormone receptor positive and has a very low level of HER2 (called HER2-ultralow). The trial aims to see if this drug can help shrink or slow the growth of the cancer in this specific group of patients.
This study tests how well trastuzumab deruxtecan (T-DXd) works for people with HER2-low breast cancer that has spread. The treatment is given as part of routine care, and the trial uses advanced imaging (PET/CT) to measure response.
This study looks at how well the drug Enhertu works for patients with HER2-low breast cancer that has spread. If you are already planning to start Enhertu, researchers will collect data from your regular care to learn more about its effectiveness.
This trial tests a combination of two targeted drugs — anlotinib (which cuts off a tumor's blood supply) and trastuzumab deruxtecan (which attacks HER2-low cancer cells) — for advanced breast cancer that has stopped responding to previous treatments.
This trial tests a combination of two drugs—trastuzumab deruxtecan (a targeted therapy) and lovastatin (a statin)—to treat advanced or metastatic breast cancer that has low levels of a protein called HER2. The goal is to see if this combination can slow or shrink the cancer.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.